Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH: Rilogrotug in Cancer Cachexia with mCRC or mNSCLC
NCT07888075Phase 3Not yet recruiting
- Sponsor
- AVEO Oncology
- Start
- Nov 2026
- Primary completion
- Mar 2030
01
Overview
A Phase 3 trial of rilogrotug in cachexia, anorexia nervosa (AN), sponsored by AVEO Oncology. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
rilogrotug
03
Conditions
cachexiaanorexia nervosa (AN)
Beyond the preview
Go deeper on NCT07888075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888075.